Understanding how MRSA affects lung function and causes injury
Official title: Pathobiology of MRSA-induced Endothelial Permeability and Acute Lung Injury
Funded at University of Illinois at Chicago · NIH-10984487 · Data updated 2026-11-12
This study is looking at how a tough bacteria called MRSA can harm the lungs and cause serious breathing problems, and it’s testing new treatments that might help protect lung cells and improve recovery for people with these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | December 20, 2022 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $596,054 |
| NIH project number | 5R01HL167518-03 |
| Project ID | NIH-10984487 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with ARDS, particularly those with sepsis caused by MRSA.
✕Less likely to help
Patients with ARDS not related to MRSA or sepsis may not benefit from this research.
What this research studies
This research investigates the mechanisms by which methicillin-resistant Staphylococcus aureus (MRSA) contributes to acute lung injury and acute respiratory distress syndrome (ARDS). The study focuses on the dysfunction of vascular endothelial cells, which play a critical role in maintaining lung health. By exploring the effects of novel compounds that enhance endothelial barrier function, the research aims to identify potential therapeutic targets for improving outcomes in patients suffering from ARDS caused by sepsis. The approach includes preclinical models to assess the efficacy of these compounds in restoring normal lung function.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve lung function and survival rates for patients with ARDS.
How similar studies have gone: Previous research has shown promise in targeting endothelial dysfunction in ARDS, but this specific approach using novel compounds is relatively novel.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Dudek, Steven M — University of Illinois at Chicago
- Study coordinator: Dudek, Steven M
Related research
Other NIH-funded projects on the same topics.
-
MSC Secretome Eye Drops to Speed Healing of Corneal Wounds
A new eye drop made from stem cell–secreted factors is being tested to help adults with non-healing corneal wounds recover vision faster.
-
UIC Center for Healthy Work
A national program led by UIC aims to improve the health and well-being of workers through collaborative research and practical solutions.
-
Coordinated Oral Health Promotion for Chicago Kids
A long-running study in Chicago is following children and their caregivers to find ways to reduce tooth decay and improve daily life for families.
-
Targeting p38 MAPK to slow ALS-related axonal damage
Aims to block a specific brain-wide signaling pathway (p38 MAPK) to reduce nerve damage in people with various genetic forms of ALS.
-
Precision nanomedicine to calm inflammation and protect bone in gum disease
A new, targeted nanomedicine approach aims to reduce gum inflammation and prevent bone loss in adults with periodontal disease.
-
Role of DPP in Dental Pulp Stem Cells and their Regenerative Potential
A project explores how a natural tooth protein helps dental pulp stem cells repair and regenerate the tooth’s inner tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.